TECNOLOGÍA PARA LA MONITORIZACIÓN Y CONTROL DE LA DIABETES

VolverVolver

Resultados 131 resultados LastUpdate Última actualización 19/04/2021 [18:32:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



Página1 de 6 nextPage   por página


NETWORK TOPOLOGY FOR INSULIN PUMP SYSTEMS

NºPublicación: US2021110907A1 15/04/2021

Solicitante:

BIGFOOT BIOMEDICAL INC [US]

CN_108601890_A

Resumen de: US2021110907A1

In one implementation, an insulin delivery system using an on-body network includes an insulin delivery device that is adapted to administer dosages of insulin to a patient; a controller that is adapted to control operation of the insulin delivery device, to establish a first network connection in which the controller acts in a central role, and to establish a second network connection in which the controller acts in a peripheral role; one or more peripheral devices that are adapted to generate patient data related to blood glucose levels and to transmit the patient data wirelessly over the first network connection, the peripheral devices acting in a peripheral role over the first network connection; and a mobile application installed on a mobile computing device that is programmed to communicate with the controller over the second network connection, the mobile application communicating in a central role over the second network connection.

traducir

GLUCOSE CONTROL SYSTEM WITH AUTOMATIC ADAPTATION OF GLUCOSE TARGET

NºPublicación: US2021106755A1 15/04/2021

Solicitante:

UNIV BOSTON [US]
MASSACHUSETTS GEN HOSPITAL [US]

JP_2020142112_A

Resumen de: US2021106755A1

A glucose control system employs adaptation of a glucose target (set-point) control variable in controlling delivery of insulin to a subject to maintain euglycemia. The glucose target adapts based on trends in actual glucose level (e.g., measured blood glucose in the subject), and/or computed doses of a counter-regulatory agent such as glucagon. An adaptation region with upper and lower bounds for the glucose target may be imposed. Generally the disclosed techniques can provide for robust and safe glucose level control. Adaptation may be based on computed doses of a counter-regulatory agent whether or not such agent is actually delivered to the subject, and may be used for example to adjust operation in a bihormonal system during periods in which the counter-regulatory agent is not available for delivery.

traducir

Stabilized Formulations Containing Anti-NGF Antibodies

NºPublicación: US2021107974A1 15/04/2021

Solicitante:

REGENERON PHARMA [US]

MX_2013000587_A

Resumen de: US2021107974A1

The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human nerve growth factor (hNGF). The formulations may contain, in addition to an anti-hNGF antibody, at least one non-ionic surfactant, at least one sugar, and acetate. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.

traducir

GLUCOSE SENSING DEVICE

NºPublicación: EP3803363A1 14/04/2021

Solicitante:

UNIV KHALIFA SCIENCE & TECHNOLOGY [AE]

WO_2019234596_PA

Resumen de: WO2019234596A1

A glucose sensor includes an insulating metal oxide layer and at least one pair of metallic electrodes arranged on the insulating metal oxide layer and separated by a gap containing the metal oxide layer. In operation, a probe including a voltage supply and current sensor can provide a voltage difference across the first and second metallic electrodes while a sample is present across the gap between the electrodes. A measured current between the first and second metallic electrodes when the voltage difference is provided can be correlated to a glucose level of the sample.

traducir

Standalone blood glucose meter

NºPublicación: US10973444B1 13/04/2021

Solicitante:

MICHAELS JEFFREY [US]

Resumen de: US10973444B1

A glucose meter includes a housing, and a first chamber and a second chamber defined in the housing. A first barrel is installed in the first chamber and adapted to accommodate multiple lancets therein. A second barrel is installed in the second chamber and adapted to accommodate multiple test strips therein. Additionally, each of the first and second chamber includes a hinged lid which is lifted to expose the first and second barrel from the top end of the first and second chamber. The hinged lids are actuated by buttons on the housing. The lancets are adapted to prick a user's finger in order to reveal blood. A user then positions the blood on the test strip to be absorbed and tested by the glucose meter.

traducir

ANALYSIS OF GLUCOSE MEDIAN, VARIABILITY, AND HYPOGLYCEMIA RISK FOR THERAPY GUIDANCE

NºPublicación: US2021100515A1 08/04/2021

Solicitante:

ABBOTT DIABETES CARE INC [US]

US_2020015756_A1

Resumen de: US2021100515A1

A system and method to provide guidance for diabetes therapy includes determining glycemic risks based on an analysis of glucose data. The analysis includes visualization of a glucose median, the variability of glucose in a patient, and the risk of hypoglycemia. An Advanced Daily Patterns report includes a visualization of an ambulatory glucose profile and a glucose control measure. The glucose control measure provides a highly visible and understandable display of the glucose condition of a patient visually expressed in the categories of low glucose, median glucose, and glucose variability.

traducir

SYSTEM AND METHOD FOR DETECTING APPLIED FORCE DURING INJECTION

NºPublicación: US2021100954A1 08/04/2021

Solicitante:

BECTON DICKINSON CO [US]

JP_2020532358_A

Resumen de: US2021100954A1

A medical device (100) includes an insulin pen (102), a pen needle (104) and a force sensor (106). The device also includes a microprocessor (206) to receive a signal from the force sensor (106). Audible and/or visual indicators (218, 220) provide feedback to a user to encourage proper injection technique. The device may also include an adaptor assembly comprising a sensor housing (306) and a first sensor (304) within the sensor housing, and a transfer needle assembly (308), the transfer needle assembly providing a connection (310) for a pen needle, and providing a fluid conduit between the pen needle (312) and the insulin pen (302). A second force sensor (314) is associated with a thumb button of the insulin pen (302).

traducir

CONTROLLER BASED ON LIFESTYLE EVENT DETECTION

NºPublicación: US2021100951A1 08/04/2021

Solicitante:

CHASE ARNOLD [US]

WO_2021067554_A1

Resumen de: US2021100951A1

A controller and associated sensor system for augmenting the automatic delivery of drugs is provided. The controller and associated sensor system is based on the detection and determination of particular physical lifestyle events. As a specific example, a pump augmentation system includes a six-axis accelerometer sensor, a gyroscopic pitch sensor and a controller. The controller is configured to receive motion data from the six-axis accelerometer sensor and orientation data from the gyroscopic pitch sensor. The controller provides a pump instruction signal for changing a delivery rate of a drug to a user based on the motion data and the orientation data. When the pump is an insulin pump, the pump augmentation system is an insulin pump augmentation system and provides accurate insulin control for controlling blood glucose levels of a user.

traducir

NEAR-IR GLUCOSE SENSORS

NºPublicación: US2021101915A1 08/04/2021

Solicitante:

PROFUSA INC [US]

JP_2020515231_A

Resumen de: US2021101915A1

Glucose-sensing luminescent dyes, polymers, and sensors are provided. Additionally, systems including the sensors and methods of using these sensors and systems are provided.

traducir

Systems and Methods for Treating Hypoglycemia

NºPublicación: US2021100952A1 08/04/2021

Solicitante:

BROWN SEAN [US]

Resumen de: US2021100952A1

Systems and methods for treating hypoglycemia generally comprise a processor and a medicament injection unit. A processor may receive continuous glucose sensor data indicative of a host's blood glucose concentration. The processor may determine whether a host's blood glucose concentration is below a predetermined threshold setting. Based at least in part on the host's blood glucose concentration, the medicament injection unit may be configured to administer a medicament to the host.

traducir

TRANSCUTANEOUS ANALYTE SENSOR

NºPublicación: US2021100452A1 08/04/2021

Solicitante:

DEXCOM INC [US]

US_2020187778_A1

Resumen de: US2021100452A1

The present invention relates generally to systems and methods for measuring an analyte in a host. More particularly, the present invention relates to systems and methods for transcutaneous measurement of glucose in a host.

traducir

Apparatus for Detecting Mating of a Cap with a Fluid Delivery Device and Method

NºPublicación: US2021100996A1 08/04/2021

Solicitante:

MEDTRONIC MINIMED INC [US]

Resumen de: US2021100996A1

This disclosure includes an apparatus for detecting mating of a cap with a fluid delivery device having a housing, a receptacle, and a sensor. The housing is configured to carry an insulin delivery device having a reservoir of the fluid. The receptacle is provided by the housing having a coupling with a locking recess configured to receive a cap with a sprung locking arm. The pressure sensor is carried by the receptacle proximate the coupling and configured to detect engagement force of the sprung locking arm with the receptacle when mated with the housing. A method is also provided.

traducir

BLOOD GLUCOSE CONTROL SYSTEM

NºPublicación: WO2021067856A1 08/04/2021

Solicitante:

BETA BIONICS INC [US]

WO_2021067767_A1

Resumen de: WO2021067856A1

A blood glucose control system is configured to modify therapy provide to a subject and determine whether the modified therapy results in a statistically significant improvement in glycemic control. The system obtains glycemic control information resulting from delivery of first therapy using a first value of a control parameter and determines a first effect corresponding to the first therapy. The control parameter is set to a second value that differs from the first value. The system obtains glycemic control information resulting from the delivery of the second therapy using the second value of the control parameter and determines a second effect corresponding to the second therapy. The system can perform a comparative assessment and determine whether the second value for the control parameter results in a statistically significant improvement in glycemic control for the subject.

traducir

COMPOSITIONS FOR INTRANASAL DELIVERY OF RELAMORELIN

NºPublicación: WO2021067819A1 08/04/2021

Solicitante:

ALLERGAN GI CORP [US]

Resumen de: WO2021067819A1

The present invention provides methods, formulations, and devices for the intranasal delivery of relamorelin. The methods, formulations, and devices of the invention may be used in the treatment of diabetic gastroparesis and its associated symptoms.

traducir

HIGH MOLECULAR WEIGHT REDOX POLYMER AND BIOSENSOR USING SAME

NºPublicación: WO2021064774A1 08/04/2021

Solicitante:

PHC HOLDINGS CORP [JP]

Resumen de: WO2021064774A1

The present disclosure provides a means for inhibiting or suppressing the outflow of a redox mediator constituting a reagent layer in a probe of an implantable biosensor, especially a means capable of improving storage stability (durability) while maintaining glucose measurement sensitivity. The high molecular weight redox polymer according to the present disclosure is represented by general formula (A) [in the formula, X- represents an anion species, L represents a linker, Poly represents a high molecular weight polymer, and R1-R8 each independently represent a hydrogen atom or a substituent.]. The biosensor according to the present disclosure has a working electrode, a counter electrode, a reagent layer disposed on the working electrode, and a protective film covering at least the reagent layer, and the reagent layer includes an oxidoreductase that oxidizes or dehydrogenates the analyte and at least one high molecular weight redox polymer represented by general formula (A).

traducir

DEVELOPMENT OF IMAGING AND THERAPEUTIC GLUCOSE ANALOGUES FOR SODIUM DEPENDENT GLUCOSE TRANSPORTERS

NºPublicación: WO2021067738A1 08/04/2021

Solicitante:

US GOV VETERANS AFFAIRS [US]
UNIV CASE WESTERN RESERVE [US]

US_2021101905_A1

Resumen de: WO2021067738A1

The present disclosure describes glucose analogs that are transported on the sodium dependent glucose transporters (SGLTs). These compounds may be useful in a variety of disorders such as, for example, cancer, heart disease, neurological disorders, diabetes, and atherosclerosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

traducir

CONTROLLER BASED ON LIFESTYLE EVENT DETECTION

NºPublicación: WO2021067554A1 08/04/2021

Solicitante:

CHASE ARNOLD [US]

US_2021100951_A1

Resumen de: WO2021067554A1

A controller and associated sensor system for augmenting the automatic delivery of drugs is provided. The controller and associated sensor system is based on the detection and determination of particular physical lifestyle events. As a specific example, a pump augmentation system includes a six-axis accelerometer sensor, a gyroscopic pitch sensor and a controller. The controller is configured to receive motion data from the six-axis accelerometer sensor and orientation data from the gyroscopic pitch sensor. The controller provides a pump instruction signal for changing a delivery rate of a drug to a user based on the motion data and the orientation data. When the pump is an insulin pump, the pump augmentation system is an insulin pump augmentation system and provides accurate insulin control for controlling blood glucose levels of a user.

traducir

LOW DOSE PREFILLED DRUG DELIVERY DEVICE AND METHOD

NºPublicación: US2021100956A1 08/04/2021

Solicitante:

BECTON DICKINSON CO [US]

ES_2684306_T3

Resumen de: US2021100956A1

A drug delivery device (100) for administering a low dose of a medicament includes a housing (111) and a drug reservoir (101) disposed in the housing (111). A needle (135) is connected to the drug reservoir (101). A pressure applying member (113) is movably connected to the housing (111) and is movable between first and second positions. The pressure applying member (113) does not apply pressure to the drug reservoir (101) in the first position and applies pressure to the drug reservoir (101) in the second position to dispense medicament stored in the drug reservoir (101). A method of administering a low dose of insulin to simulate a first-phase insulin response of a pancreas is also disclosed.

traducir

NON-INVASIVE DETERMINATION OF GLUCOSE

NºPublicación: WO2021063696A1 08/04/2021

Solicitante:

GLUCO TERA TECH AG [CH]

WO_2021063695_A1

Resumen de: WO2021063696A1

The present invention relates to the non-invasive determination of glucose in blood, in particular to the non-invasive determination of glucose in capillary blood.

traducir

SYSTEM FOR PREDICTING A PATIENT'S BLOOD GLUCOSE LEVEL

NºPublicación: US2021100486A1 08/04/2021

Solicitante:

COMMISSARIAT A IENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES [FR]

KR_20200133231_A

Resumen de: US2021100486A1

An automated blood glucose control system, including a processing and control unit capable of predicting, based on a mathematical model, the future trend of the patient's blood glucose G(t), wherein the model takes as inputs: a variable EE(t) representative of the time variation of the patient's energy expenditure; variable IOB(t) representative of the time variation of the patient's quantity of insulin on board; and a variable COB(t) representative of the time variation of the patient's quantity of glucose on board, and wherein the mathematical model is a model of black box type, that is, a non-physiological model only defined by the observation of the effects of input variables EE(t), IOB(t) and COB(t) on output variable G(t), without taking into account the different known physiological mechanisms operating in the patient's body.

traducir

Non-Invasive system for testing blood sugar and method of the same

NºPublicación: GB2587656A 07/04/2021

Solicitante:

ETOUCH MEDICAL INC [TW]

Resumen de: GB2587656A

Disclosed is a system for non-invasively testing blood sugar or glucose of a user using a case which is electrical insulation and water proof which accommodates a control key unit for allowing the user to control the system. The case also accommodates an input electrode unit comprising two input electrodes for contacting the user and generating an input signal; a signal filter receiving the input signal and generating a filtered signal; a signal transformation unit for receiving the filtered signal and generated a digital converted signal; a control processing unit for receiving the converted signal and generating blood sugar information, the CPU generating a trigger signal; a signal amplification unit for receiving the trigger signal and generating a trigger amplified signal; an output electrode unit comprising two output electrodes receiving the trigger amplified signal and generating a trigger driving signal to the user, wherein the input signal of the input electrodes corresponds to the trigger driving signal; and a driver for receiving blood sugar information and generating a display driving signal and transferring to a display unit which displays the driving signal. In one aspect the trigger signal is a square wave with a frequency of 100-500Hz. Another aspect relates to a method of using the system and calculating blood glucose (GLU) of a user from blood sugar information obtained from input feedback signals.

traducir

ONBOARDING AND TOTAL DAILY INSULIN ADAPTIVITY

NºPublicación: US2021098105A1 01/04/2021

Solicitante:

INSULET CORP [US]

WO_2021061711_A1

Resumen de: US2021098105A1

Disclosed are a device, a computer-readable medium, and techniques that provide an onboarding process and an adaptivity process for a drug delivery device. A processor executing an onboarding process determines whether a history of delivered insulin to a user meets certain sufficiency requirements. The onboarding process enables a processor to cause the drug delivery device to administer doses of insulin to a user according to an initial total daily insulin dose calculation that is determined based on the sufficiency of the insulin delivery history. The initial total daily insulin may be adapted according to the adaptivity process as new insulin delivery is collected. The insulin delivery history, when sufficient, may be used to set total daily insulin dosages that enable automated insulin delivery upon replacement of a drug delivery device. The adaptivity process may be implemented to modify an initial insulin delivery doses to provide adapted insulin delivery doses.

traducir

SYSTEM AND METHOD FOR MITIGATING RISK IN AUTOMATED MEDICAMENT DOSING

NºPublicación: US2021093782A1 01/04/2021

Solicitante:

TANDEM DIABETES CARE INC [US]

US_2018110921_A1

Resumen de: US2021093782A1

A portable infusion pump can communicate with glucose monitor, such as a continuous glucose monitor (CGM), to receive continuous feedback relating to a user's blood glucose level during insulin or other medicament therapy and can automatically deliver insulin to a user when the CGM data indicates a need for additional insulin. Due to potential unreliability in the correlation of the CGM data to the user's actual blood glucose level, risk mitigation can be employed to limit the amount of extra insulin that can be delivered by the pump in response to the CGM data.

traducir

FLUID INFUSION SYSTEM THAT AUTOMATICALLY DETERMINES AND DELIVERS A CORRECTION BOLUS

NºPublicación: US2021093783A1 01/04/2021

Solicitante:

MEDTRONIC MINIMED INC [US]

AU_2019349568_A1

Resumen de: US2021093783A1

A method of controlling an insulin infusion device involves controlling the device to operate in an automatic basal insulin delivery mode, obtaining a blood glucose measurement for the user, and initiating a correction bolus procedure when: the measurement exceeds a correction bolus threshold value; and a maximum basal insulin infusion rate is reached during the automatic basal insulin delivery mode. The correction bolus procedure calculates an initial correction bolus amount, and scales the initial amount to obtain a final correction bolus amount, such that a predicted future blood glucose level resulting from simulated delivery of the final correction bolus amount exceeds a low blood glucose threshold level. The final amount is delivered to the user during operation in the automatic basal insulin delivery mode.

traducir

APPARATUS FOR DETERMINING BLOOD AND CARDIOVASCULAR CONDITIONS AND METHOD FOR USING THE SAME

Nº publicación: US2021093206A1 01/04/2021

Solicitante:

VITA COURSE TECH CO LTD [CN]

CN_112312832_A

Resumen de: US2021093206A1

A blood and cardiovascular condition determination apparatus is provided. The blood and cardiovascular condition determination apparatus may include a first pulse wave signal sensor, a second pulse wave signal and a processing unit. The first pulse wave signal sensor may be configured to generate a first pulse wave signal associated with a first section of a living body. The second pulse wave signal sensor may be configured to generate a second pulse wave signal associated with a second section of the living body. The processing unit may determine at least one blood and cardiovascular condition based on the first pulse wave signal and the second pulse wave signal. The at least one blood and cardiovascular condition may include at least one of a blood pressure, a blood sugar level, a blood oxygen level, a blood vessel aging level, or a blood viscosity.

traducir

Página1 de 6 nextPage por página

punteroimgVolver